US 12,458,242 B2
Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
Frederico P. Costa, Sao Paulo (BR)
Assigned to THERABIONIC, INC., Winston-Salem, NC (US)
Filed by TheraBionic, Inc., Winston-Salem, NC (US)
Filed on Feb. 27, 2023, as Appl. No. 18/175,021.
Application 18/175,021 is a continuation of application No. 16/853,173, filed on Apr. 20, 2020, granted, now 11,589,765, issued on Feb. 28, 2023.
Application 16/853,173 is a continuation of application No. 15/569,312, granted, now 10,624,546, issued on Apr. 21, 2020, previously published as PCT/US2016/028880, filed on Apr. 22, 2016.
Application 15/569,312 is a continuation of application No. 14/545,377, filed on Apr. 28, 2015, abandoned.
Prior Publication US 2023/0218188 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/00 (2006.01); A61B 5/021 (2006.01); A61B 5/0265 (2006.01); A61B 5/029 (2006.01); A61B 5/352 (2021.01); A61N 1/40 (2006.01); A61N 5/02 (2006.01); A61B 5/02 (2006.01); A61B 5/0245 (2006.01); A61B 5/0255 (2006.01)
CPC A61B 5/029 (2013.01) [A61B 5/021 (2013.01); A61B 5/0265 (2013.01); A61B 5/352 (2021.01); A61N 1/403 (2013.01); A61N 5/025 (2013.01); A61B 5/02007 (2013.01); A61B 5/02108 (2013.01); A61B 5/02141 (2013.01); A61B 5/0245 (2013.01); A61B 5/0255 (2013.01); A61N 5/022 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A system for diagnosing a cancer type in a patient, comprising:
a hemodynamic parameter (Hdp) monitor that measures Hdp values exhibited by the patient during (i) a non-exposure period and (ii) during an exposure period during which the patient is exposed to amplitude-modulated radio-frequency electromagnetic field (EMF) output signals, wherein the Hdp values comprise a pressure component, a flow component and a beat component;
an electrically-powered generator to generate the amplitude-modulated radio-frequency EMF output signals for exposing to the patient during the exposure period, comprising an amplitude modulation controller for controlling the amplitude of the amplitude-modulated radio-frequency EMF output signals;
a probe connected to the electrically powered generator through which the patient is exposed to the amplitude-modulated radio-frequency EMF output signals during the exposure period; and
a storage system comprising predetermined Hdp values comprising the pressure component, flow component and beat component from one or a plurality of surrogate patients pre-diagnosed with the cancer type, wherein the Hdp values were exhibited by the surrogate patient during (i) a non-exposure period and (ii) during an exposure period during which the surrogate patient was exposed to the amplitude-modulated radio-frequency EMF output signals, and which storage system is adapted to allow for comparison of the Hdp values of the patient and the surrogate patient(s).